Literature DB >> 21036646

Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology.

Maxime Samson1, Sylvain Audia, Daniela Lakomy, Bernard Bonnotte, Christian Tavernier, Paul Ornetti.   

Abstract

The discovery of hypogammaglobulinemia, which is defined as a plasmatic level of immunoglobulin (Ig) under 5 g/L is rare in clinical practice. However, the management of immunodepressed patients in rheumatology, sometimes due to the use of immunosuppressive treatments such as anti-CD20 in chronic inflammatory rheumatisms, increases the risk of being confronted to this situation. The discovery of hypogammaglobulinemia in clinical practice, sometimes by chance, must never be neglected and requires a rigorous diagnosis approach. First of all, in adults, secondary causes, in particular lymphoid hemopathies or drug-related causes (immunosuppressors, antiepileptics) must be eliminated. A renal (nephrotic syndrome) or digestive (protein-losing enteropathy) leakage of Ig is also possible. More rarely, it is due to an authentic primary immunodeficiency (PID) discovered in adulthood: common variable immunodeficiency (CVID) which is the most frequent form of PID, affects young adults between 20 and 30 years and can sometimes trigger joint symptoms similar to those in rheumatoid arthritis; or Good syndrome, which associates hypogammaglobulinemia, thymoma and recurrent infections around the age of 40 years. In most cases, after confirming hypogammaglobulinemia on a second test, biological examinations and thoracic-abdominal-pelvic CT scan will guide the diagnosis, after which the opinion of a specialist can be sought depending on the findings of the above examinations. At the end of this review, we provide a decision tree to guide the clinician confronted to an adult-onset hypogammaglobulinemia.
Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21036646     DOI: 10.1016/j.jbspin.2010.09.016

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  8 in total

1.  Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases.

Authors:  Emilio Besada; Lucius Bader; Hans Nossent
Journal:  Rheumatol Int       Date:  2011-12-30       Impact factor: 2.631

Review 2.  Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Authors:  Ewa Więsik-Szewczyk; Aleksandra Kucharczyk; Katarzyna Świerkocka; Elżbieta Rutkowska; Karina Jahnz-Różyk
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

3.  Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency.

Authors:  Clemens Wirsum; Cornelia Glaser; Sylvia Gutenberger; Baerbel Keller; Susanne Unger; Reinhard E Voll; Werner Vach; Thomas Ness; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2016-03-15       Impact factor: 8.317

Review 4.  Case report and literature review on Good's syndrome, a form of acquired immunodeficiency associated with thymomas.

Authors:  Mark Henry Joven; Melvin P Palalay; Charlie Y Sonido
Journal:  Hawaii J Med Public Health       Date:  2013-02

5.  Complex regional pain syndrome treated with intravenous immunoglobulin in a patient with common variable immune deficiency.

Authors:  Raffi Tachdjian
Journal:  Pain Ther       Date:  2013-12-05

6.  [Acquired hypogammaglobulinemia associated with thymoma: Good syndrome].

Authors:  Samira Aouadi; Najla Ghrairi; Emna Braham; Manel Kaabi; Sonia Maâlej; Leila Douik Elgharbi
Journal:  Pan Afr Med J       Date:  2017-11-22

7.  Clostridium difficile septic arthritis and periprosthetic joint infection in a patient with acute lymphoblastic leukaemia, T-/B-lymphocytopenia and hypogammaglobulinemia - a case report and review of the literature.

Authors:  Daniel Karczewski; Maximilian Müllner; Carsten Perka; Michael Müller
Journal:  Access Microbiol       Date:  2021-05-10

8.  Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

Authors:  A Razzaque Ahmed; Srinivas Kaveri
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.